Novel combination immunotherapy for relapsed/refractory multiple myeloma: initial Phase I safety run-in results for cevostamab in combination with pomalidomide and dexamethasone
CAMMA 1 is an ongoing Phase Ib study evaluating the safety and activity of cevostamab alone (Arm A) or with pomalidomide + dexamethasone (Arm B) or daratumumab + dexamethasone (Arm C) in patients with RRMM. Initial data from the Arm B safety run-in are presented.
You are Leaving Medically
By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.
You are Leaving the Global Medically Site
By following this link, you are being redirected to another Roche page.